1. Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort 
Elaine Kunzler, MD, Stephanie Florez-Pollack, BS, Noelle Teske, MD, MSc, Jack O'Brien, MD, Smriti Prasad, BS, Heidi Jacobe, MD, MSCS 
Journal of the American Academy of Dermatology 
Volume 80, Issue 6, Pages e1 (June 2019)
DOI: /j.jaad
Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1
Median quality of life and LoSCAT component scores in linear morphea participants over time. Paired scores were analyzed over a 3-year follow-up period. CDLQI and DLQI scores significantly improved between the baseline and 3-year follow-up study visits (P < .001 and P = .006, respectively). Activity (measured by mLoSSI and PGA-A) decreased significantly over time (P < .001). LoSDI scores showed a trend to increase; however, this did not reach significance (P = .42). Median PGA-D scores minimally decreased from 30 (IQR 20-50) at baseline to 27 (IQR 20-40) at 3-year follow-up (P < .001). CDLQI, Children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; IQR, interquartile range; LoSDI, Localized Scleroderma Damage Index; mLoSSI, modified Localized Scleroderma Skin Severity Index; PGA-A, Physician Global Assessment of Disease Activity; PGA-D, Physician Global Assessment of Disease Damage.
Journal of the American Academy of Dermatology  , e1DOI: ( /j.jaad )
Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

3. Fig 2
mLoSSI and LoSDI scores in patients with pediatric and adult-onset linear morphea over time. A, Median scores for both groups decreased from baseline to first annual study visit and remained stable. B, LoSDI scores showed a trend to increase over time. LoSDI, Localized Scleroderma Damage Index; mLoSSI, modified Localized Scleroderma Skin Severity Index.
Journal of the American Academy of Dermatology  , e1DOI: ( /j.jaad )
Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions